|
Delayed
Nasdaq
16:00:00 2025-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 5.670 USD | -.--% |
|
-.--% | - |
| 25-10-07 | MannKind Corporation completed the acquisition of scPharmaceuticals Inc.. | CI |
| 25-10-07 | MannKind Completes Acquisition of scPharmaceuticals | MT |
| Market Cap | 305M 268M 254M 230M 433M 29.23B 438M 3.04B 1.17B 14.94B 1.14B 1.12B 47.9B | P/E 2023 |
-4.41x | P/E 2024 | -1.85x |
|---|---|---|---|---|---|
| Enterprise Value | 281M 247M 234M 212M 399M 26.93B 404M 2.8B 1.08B 13.77B 1.05B 1.03B 44.14B | EV / Sales 2023 |
13,839,720x | EV / Sales 2024 | 4,215,542x |
| Free-Float |
98.42% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 year | 5.64 |  | 5.7 |
| 3 years | 1.94 | | 7.1 |
| 5 years | 1.94 | | 12.75 |
| 10 years | 1.94 | | 18.17 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 49 | 2025-10-06 |
| Director of Finance/CFO | 50 | 2025-10-06 | |
David Thomson
SEC | Corporate Secretary | 59 | 2025-10-06 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Castagna
BRD | Director/Board Member | 49 | 2025-10-06 |
David Thomson
BRD | Director/Board Member | 59 | 2025-10-06 |
| Director/Board Member | 50 | 2025-10-06 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/7/25 | Issuer sale | Director | 72,174 | 0.1442% | ||
| 10/7/25 | Issuer sale | Director | 84,422 | 0.1687% | ||
| 10/7/25 | Issuer sale | Director | 49,750 | 0.0994% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | -.--% | -20.37% | 305M | |
| -0.92% | +0.53% | +51.65% | +115.42% | 1,031B | |
| -0.80% | -1.65% | +42.78% | +69.98% | 638B | |
| -0.88% | -1.32% | +12.98% | +75.49% | 462B | |
| -0.67% | -1.87% | +73.13% | +41.15% | 359B | |
| +0.44% | -3.30% | +24.48% | +41.66% | 335B | |
| -1.18% | +0.12% | +14.50% | +27.56% | 273B | |
| -1.26% | -1.89% | -2.17% | +11.11% | 253B | |
| -0.78% | +3.80% | +49.37% | +56.84% | 228B | |
| -0.53% | -1.53% | +34.28% | +98.89% | 185B | |
| Average | -0.42% | -0.33% | +30.10% | +51.77% | 376.42B | |
| Weighted average by Cap. | -0.54% | -0.35% | +37.72% | +71.42% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 13.59 11.97 11.34 10.24 19.3 1.3K 19.55 135.69 52.22 666.29 51.04 49.93 2.14K | 36.33 31.99 30.31 27.37 51.58 3.48K 52.25 362.68 139.57 1.78K 136.43 133.45 5.71K |
| Net income | -54.81M -48.27M -45.73M -41.28M -77.81M -5.26B -78.82M -547M -211M -2.69B -206M -201M -8.61B | -85.15M -74.98M -71.04M -64.14M -121M -8.16B -122M -850M -327M -4.17B -320M -313M -13.38B |
| Net Debt | -36.72M -32.34M -30.64M -27.66M -52.13M -3.52B -52.81M -367M -141M -1.8B -138M -135M -5.77B | -23.98M -21.12M -20.01M -18.06M -34.05M -2.3B -34.49M -239M -92.13M -1.18B -90.06M -88.09M -3.77B |
Employees
163
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SCPH Stock
Select your edition
All financial news and data tailored to specific country editions
